Prophylaxis with tetracyclines to prevent papulopustular rash associated with inhibitors of epidermic growth factor receptor
Keywords:
EGFR inhibitors, EGFR, papulo-pustular eruption, prevention, tetracyclines, clinical trials.Abstract
Introduction: The purpose of this review was to evaluate if the prophylaxis with tetracyclines as a monotherapy or associated to another dermatological agent has an impact in the reduction of papulo-pustular rash in patients with an oncological disease that are going to receive epidermal growth factor receptor inhibitors (EGFRi).
Matherials and methods: A systematic review of randomized trials was carried out assessing preventive efficacy of tetracyclines.
Results: Four randomized trials were selected, comparing prophylaxis with tetracyclines versus placebo or reactive treatment, showing a tendency to lower incidence of rash without statistically significance, except one study that was associated with a decreased incidence of rash grade ≥2.
Conclusions: Due to the small number of randomized trials and the heterogeneity of the patients in those studies it is not possible to generate a recommendation about prophylaxis with tetracyclines for patients treated with an EGFRi, therefore, it is necessary to conduct more randomized clinical trials.
Author Biographies
Claudia Liliana Montoya
Médica, residente de primer año, Servicio de Dermatología, Fundación Valle de Lili-Universidad ICESI, Cali, Colombia
Andrés Vidal
Médico dermatólogo, Fundación Valle del Lili, Cali, Colombia
Magda Cepeda
Médica epidemióloga, Unidad de Investigaciones Clínicas, Fundación Valle del Lili, Cali, Colombia
References
1. Giovannini M, Gregorc V, Belli C, Roca E, Lazzari C, Viganò MG, et al. Clinical significance of skin toxicity due to EGFR-targeted therapies. J Oncol. 2009:849051.
2. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001; 144: 1169-76.
3. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature reviews. Cancer. 2006;6:803-12.
4. Joshi SS, Ortiz S, Witherspoon JN, Rademaker A, West DP, Anderson R, et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer. 2010;116:3916-23.
5. Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: Survey results. Oncology. 2007;72:152-9.
6. Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT, et al. Interdisciplinary management of EGFR-inhibitorinduced skin reactions: A German expert opinion. Ann Oncol. 2011;22:524-35.
7. Segaert S, van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16:1425-33.
8. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6:491-500.
9. Galimont-Collen AFS, Vos LE, Lavrijsen APM, Ouwerkerk J, Gelderblom H. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer. 2007;43:845-51.
10. Pérez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology. 2003;17(Suppl.12):23-8.
11. Racca P, Fanchini L, Caliendo V, Ritorto G, Evangelista W, Volpatto R, et al. Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: Outcomes from an oncologic/dermatologic cooperation. Clin Colorectal Cancer. 2008;7:48-54.
12. Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007;56:317-26.
13. Bachet JB, Peuvrel L, Bachmeyer C, Reguiai Z, Gourraud PA, Bouché O, et al. Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: A systematic literature review. Oncologist. 2012;17:555-68.
14. Jatoi A, Dakhil SR, Sloan JA, Kugler JW, Rowland KM, Schaefer PL, et al. Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: Results from the North Central Cancer Treatment Group (Supplementary N03CB). Support Care Cancer. 2011;19:1601-7.
15. Lacouture ME, Anadkat MJ, Bensadoun R-J, Bryce J, Chan A, Epstein JB, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19:1079-95.
16. Fernández-Guarino M, Pérez B, Aldanondo I, García-Millán C, Garrido P, Jaén P. Treatment of acneiform rash by epidermal growth factor inhibitors with oral tetracyclines. Actas Dermosifiliográficas. 2006;97:503-8.
17. Baas JM, Krens LL, Guchelaar H-J, Ouwerkerk J, de Jong FA, Lavrijsen APM, et al. Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review. Cancer Treat Rev. 2012;38:505-14.
18. Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer. 2008;113:847-53.
19. Scope A, Agero ALC, Dusza SW, Myskowski PL, Lieb JA, Saltz L, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007;25:5390-6.
20. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:1351-7.
21. Luu M, Lai SE, Patel J, Guitart J, Lacouture ME. Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib. Photodermatol Photoimmunol Photomed. 2007;23:42-5.
22. Duvic M. EGFR inhibitor-associated acneiform folliculitis: Assessment and management. Am J Clin Dermatol. 2008;9:285-94.
2. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001; 144: 1169-76.
3. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature reviews. Cancer. 2006;6:803-12.
4. Joshi SS, Ortiz S, Witherspoon JN, Rademaker A, West DP, Anderson R, et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer. 2010;116:3916-23.
5. Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: Survey results. Oncology. 2007;72:152-9.
6. Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT, et al. Interdisciplinary management of EGFR-inhibitorinduced skin reactions: A German expert opinion. Ann Oncol. 2011;22:524-35.
7. Segaert S, van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16:1425-33.
8. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6:491-500.
9. Galimont-Collen AFS, Vos LE, Lavrijsen APM, Ouwerkerk J, Gelderblom H. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer. 2007;43:845-51.
10. Pérez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology. 2003;17(Suppl.12):23-8.
11. Racca P, Fanchini L, Caliendo V, Ritorto G, Evangelista W, Volpatto R, et al. Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: Outcomes from an oncologic/dermatologic cooperation. Clin Colorectal Cancer. 2008;7:48-54.
12. Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007;56:317-26.
13. Bachet JB, Peuvrel L, Bachmeyer C, Reguiai Z, Gourraud PA, Bouché O, et al. Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: A systematic literature review. Oncologist. 2012;17:555-68.
14. Jatoi A, Dakhil SR, Sloan JA, Kugler JW, Rowland KM, Schaefer PL, et al. Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: Results from the North Central Cancer Treatment Group (Supplementary N03CB). Support Care Cancer. 2011;19:1601-7.
15. Lacouture ME, Anadkat MJ, Bensadoun R-J, Bryce J, Chan A, Epstein JB, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19:1079-95.
16. Fernández-Guarino M, Pérez B, Aldanondo I, García-Millán C, Garrido P, Jaén P. Treatment of acneiform rash by epidermal growth factor inhibitors with oral tetracyclines. Actas Dermosifiliográficas. 2006;97:503-8.
17. Baas JM, Krens LL, Guchelaar H-J, Ouwerkerk J, de Jong FA, Lavrijsen APM, et al. Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review. Cancer Treat Rev. 2012;38:505-14.
18. Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer. 2008;113:847-53.
19. Scope A, Agero ALC, Dusza SW, Myskowski PL, Lieb JA, Saltz L, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007;25:5390-6.
20. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:1351-7.
21. Luu M, Lai SE, Patel J, Guitart J, Lacouture ME. Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib. Photodermatol Photoimmunol Photomed. 2007;23:42-5.
22. Duvic M. EGFR inhibitor-associated acneiform folliculitis: Assessment and management. Am J Clin Dermatol. 2008;9:285-94.
How to Cite
1.
Montoya CL, Vidal A, Cepeda M. Prophylaxis with tetracyclines to prevent papulopustular rash associated with inhibitors of epidermic growth factor receptor. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 2019 Aug. 9 [cited 2024 Jul. 3];21(1):69-75. Available from: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/1004
Downloads
Download data is not yet available.
Downloads
Published
2019-08-09
How to Cite
1.
Montoya CL, Vidal A, Cepeda M. Prophylaxis with tetracyclines to prevent papulopustular rash associated with inhibitors of epidermic growth factor receptor. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 2019 Aug. 9 [cited 2024 Jul. 3];21(1):69-75. Available from: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/1004
Issue
Section
Topic review
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
